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Introduction
Inflammasomes are large, multiprotein complexes that form upon 
cytosolic or nuclear presence of damage- or pathogen-associated 
molecular patterns, ultimately leading to the secretion of IL-1β 
and IL-18. Inflammasomes consist of a danger-sensing receptor, 
the adaptor molecule ASC, and the protease caspase-1. Assembly 
of the inflammasome complex results in autocleavage and activa-
tion of caspase-1, which cleaves pro–IL-1β and pro–IL-18 into their 
active forms and mediates their secretion (1). Several NOD-like 
receptor (NLR) proteins, including NLRP3, NLRP1, NLRC4, and 
absent in melanoma 2 (AIM2), are able to form inflammasomes and 
induce subsequent IL-1β secretion (2). All these receptors have sim-
ilar structures, containing an N-terminal caspase recruitment and 
activation domain (CARD) or a pyrin domain (PYD) that mediates 
interaction with downstream proteins; a nucleotide oligomerization 
domain (NOD; not present in AIM2) that allows oligomerization 
upon activation; and one or several leucine-rich repeats (LRRs) or, 
in the case of AIM2, a HIN domain, which are involved in ligand 
binding and activation of the receptor. Upon activation, inflam-
masome receptors containing a CARD directly recruit caspase-1, 
while inflammasome receptors containing a PYD rely on the adap-
tor molecule ASC for caspase-1 recruitment and activation. Each 
inflammasome-associated danger-sensing receptor is activated by 
specific ligands, including the NLRC4 ligand flagellin; bacterial 
products in the case of NLRP1; or double-stranded DNA (dsDNA) 
that activates AIM2. NLRP3 is activated by a variety of different 
molecules, including muramyl dipeptide (MDP), titanium dioxide 
(TiO2), silicium dioxide (SiO2), monosodium urate crystals (MSUs), 
and extracellular ATP (3). The mechanism whereby NLRP3 is acti-
vated by this variety of compounds is still not understood, but pro-
duction of ROS and potassium efflux have been described as media-
tors leading to NLRP3 activation. Recent reports demonstrated that 
tyrosine phosphorylation of ASC acts as a molecular switch for acti-
vation of inflammasome assembly (4), and serine phosphorylation 
of NLRC4 has been shown to be important for its activation (5). This 
demonstrates that the phosphorylation status of certain proteins in 
the inflammasome complex influence inflammasome activity.
Deregulated NLRP3 activation is detrimental for the host, 
and several immune disorders have been associated with aber-
rant NLRP3 activation, including Crohn’s disease (CD) (6), sys-
temic lupus erythematosus (SLE), rheumatoid arthritis (RA), and 
type 1 diabetes (T1D) (3, 7). In most cases, increased NLRP3 acti-
vation results in uncontrolled inflammation that drives disease 
progression (3), but in intestinal inflammation, NLRP3 activation 
seems to play a dual role. While exacerbated IL-1β/IL-18 secre-
tion is observed in active lesions from patients with inflamma-
tory bowel diseases (IBDs) (8), and NLRP3-deficient animals 
have been shown to have less severe experimental colitis in some 
reports (9), other groups reported defective epithelial barrier 
function and increased intestinal inflammation in NLRP3-defi-
cient animals (10). Further, mice deficient for the inflammasome 
adaptor molecule ASC or for caspase-1 have epithelial barrier 
defects and increased intestinal inflammation, and it has been 
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Results
Loss of PTPN22 reduces mature IL-1β secretion. To assess a possible 
effect of PTPN22 on inflammasome activation, we first tested 
whether loss of PTPN22 influences IL-1β secretion. Knockdown of 
PTPN22 was induced in THP-1 cells by transfection with a lentivi-
ral vector encoding either nonrelevant control or PTPN22-specific 
shRNA. After selection of stable shRNA-expressing clones, the 
cells were differentiated for 48 hours with PMA; pretreated for 12 
hours with ultrapure LPS (upLPS); and activated with the NLRP3 
inflammasome activators MDP (100 ng/ml, 24 hours), MSU (150 
μg/ml, 6 hours), SiO2 (150 μg/ml, 6 hours), TiO2 (150 μg/ml, 
6 hours), and ATP (2 mM, 30 minutes). In response to all treat-
ments, PTPN22 knockdown resulted in a significant reduction of 
agonist-induced IL-1β release (Figure 1A). Since inflammasome 
activation induces pyroptosis, an inflammation-associated form 
of cell death, reduction of inflammasome activity is expected to 
result in reduced cell lysis. Despite decreased inflammasome acti-
vation, release of lactate dehydrogenase (LDH), a general marker 
of cell damage, was not affected by loss of PTPN22 (Figure 1A). 
Therefore, we hypothesized that PTPN22 might induce another 
form of cell death. To address possible mechanisms, we analyzed 
the cells for the apoptosis marker caspase-3. Since there was an 
increase in levels of cleaved caspase-3 (Figure 1B), we suggest 
that loss of PTPN22 might promote apoptosis, but more detailed 
analyses would be necessary to draw a final conclusion. Since 
secretion of other inflammatory cytokines, such as IL-6 or TNF, 
was enhanced or remained unchanged by loss of PTPN22 (Figure 
suggested that inflammasome activation mediates intestinal 
wound healing and epithelial cell reconstitution (11).
Variations within the gene locus encoding protein tyrosine 
phosphatase non-receptor 22 (PTPN22) are associated with 
several inflammatory disorders, including CD (12), RA (13), SLE 
(14), and T1D (15), diseases linked with altered inflammasome 
function (6, 16). Of note, a variant that results in in vitro gain-of-
function phosphatase activity (17) in PTPN22 is associated with 
decreased risk for CD (12, 18, 19) while resulting in enhanced sus-
ceptibility to RA (20) and SLE (14). We previously demonstrated 
that PTPN22 expression is reduced in patients with IBD (21), and 
knockdown of PTPN22 results in increased secretion of proin-
flammatory cytokines including IL-6 and IL-8 (21, 22). Further, 
PTPN22 is involved in autophagy activation and MDP-induced 
signaling and cytokine secretion (22). A study by Wang et al. 
showed that knockout of PTPN22 results in enhanced suscepti-
bility to experimental arthritis as well as DSS-induced colitis (23). 
However, a functional role for PTPN22 in inflammasome activa-
tion and IL-1β secretion has not been addressed so far.
Here we report what we believe to be a novel regulatory mech-
anism of NLRP3 inflammasome activation, mediated by tyrosine 
phosphorylation of NLRP3 on Tyr861. We found that PTPN22 
interacts with and dephosphorylates NLRP3 upon proinflamma-
tory insults, allowing robust NLRP3 activation and IL-1β secre-
tion. In PTPN22-deficient cells and mice, NLRP3 phosphorylation 
was enhanced and inflammasome assembly reduced, resulting in 
decreased IL-1β secretion.
Figure 1. Knockdown of PTPN22 
reduces IL-1β secretion. PTPN22 
knockdown was induced in THP-1 
cells using lentiviral shRNA 
expression vectors. Cells were 
pretreated for 12 hours with 
upLPS before activation with 
MDP (100 ng/ml, 24 hours), MSU 
(150 ng/ml, 6 hours), TiO2 (150 
ng/ml, 24 hours), SiO2 (150 ng/
ml, 12 hours), or ATP (200 mM, 30 
minutes). (A) Cell culture super-
natants were analyzed for IL-1β 
secretion, LDH release, and IL-6 
secretion by ELISA. (B) Cell lysates 
or supernatants were analyzed 
for caspase-1 (Casp-1), caspase-3 
(Casp-3), IL-1β, NLRP3, ASC, and 
PTPN22 expression. Blots for 
IL-1β were run on the same gel 
but were discontinuous. Data are 
representative of 1 of at least 3 
independent experiments with 
3–5 replicas (n = 3–5; *P < 0.05, 
**P < 0.01; Newman-Keuls post 
hoc test). Numbers below the 
blots show results of densitome-
try (cleaved forms).
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marrow–derived macrophages (BMDMs) from PTPN22-knock-
out (Ptpn22–/–) mice ex vivo: BMDCs and BMDMs derived from 
Ptpn22–/– mice secreted less mature IL-1β in response to SiO2 or 
MSU than BMDCs/BMDMs from WT mice, while IL-6 secretion 
was enhanced and TNF secretion remained unchanged (Figure 2, 
A and B, and Supplemental Figure 2A). Again, LDH release was 
similar in the two genotypes (Supplemental Figure 2A), while lev-
els of cleaved caspase-1 and mature IL-1β were lower in BMDCs/
BMDMs from Ptpn22–/– animals than in those from WT animals 
treated with either SiO2 or MSU (Figure 2, A and B). On the other 
hand, BMDCs/BMDMs from mice expressing the autoimmuni-
ty-associated variant in PTPN22 (619W mice) showed increased 
levels of cleaved caspase-1/IL-1β and enhanced IL-1β secretion 
(Figure 2). Of note, the autoimmunity-associated variant was 
initially described to result in a gain-of-function protein (17), 
although some newer studies indicate an in vivo loss-of-function 
effect in T cell biology (24) and altered effects in T lymphocyte, B 
lymphocyte, and dendritic cell biology (25). Of note, Western blot 
analysis of cell lysates did not reveal changes in pro–IL-1β, NLRP3, 
or pro–caspase-1 protein levels, while ASC levels were enhanced 
in PTPN22-deficient cells (Figure 1B and Figure 2).
1A and Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI83669DS1), the decrease 
in IL-1β secretion seemed to result not merely from changes in 
cell death. To determine whether the observed reduction in IL-1β 
was due to reduced levels of pro– or cleaved IL-1β, we subjected 
cell culture supernatants and cell lysates to Western blot analysis. 
While cell damage–mediated release of pro–IL-1β and pro–cas-
pase-1 was not changed upon loss of PTPN22, levels of mature 
IL-1β, as well as of cleaved caspase-1, were reduced (Figure 1B). 
The reduction in mature IL-1β was more pronounced in the West-
ern blot analysis compared with the ELISA measurement (Figure 
1, A and B). This is because IL-1β ELISA detects not only mature 
IL-1β but also pro–IL-1β, and the dynamic range of the ELISA is 
several magnitudes higher than that of the Western blot. Similar 
IL-1β secretion results were obtained in SiO2- and MSU-treated 
human MM6 monocytic cells (Supplemental Figure 1B) and in 
ultraviolet light–treated (UV-treated) primary human keratino-
cytes transfected with either control or PTPN22-targeting siRNA 
(Supplemental Figure 1C; note that keratinocytes express PTN22, 
although they are not of hematopoietic origin), as well as in pri-
mary bone marrow–derived dendritic cells (BMDCs) and bone 
Figure 2. Loss of PTPN22 reduces and presence of the PTPN22-619W variant enhances IL-1β secretion. (A) BMDCs and (B) BMDMs were derived from 
Ptpn22–/– (N22–/–) and WT littermates, or mice expressing the autoimmunity-associated PTPN22 variant (619W), pretreated for 12 hours with upLPS prior 
to activation with MSU or SiO2, and analyzed for IL-1β and IL-6 release by ELISA, as well as caspase-1/IL-1β cleavage by Western blot. Data are representa-
tive of 1 of at least 3 independent experiments with 3–5 replicas (n = 3–5; *P < 0.05, **P < 0.01; Newman-Keuls post hoc test). Numbers below the blots 
show results of densitometry (cleaved forms). Ctr, control.
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PTPN22 expression upon LPS treatment, and indeed, after 8 
hours of upLPS treatment, Ptpn22 mRNA levels were reduced in 
WT BMDCs. However, after 2 hours and 16 hours Ptpn22 mRNA 
expression was increased, and PTPN22 protein levels were clearly 
enhanced upon upLPS treatment at all analyzed time points (Sup-
plemental Figure 2, D and E). Further, and in line with other pub-
lications (23, 27, 28), both loss of PTPN22 and the presence of the 
autoimmunity-associated variant resulted in decreased induction 
of type I IFN (Supplemental Figure 2D). Since type I IFNs are 
involved in caspase-11 induction (29), and caspase-11 is involved 
in noncanonical IL-1β cleavage/secretion upon LPS treatment (29, 
30), we further addressed expression/cleavage of caspase-11. In 
our hands, upLPS robustly induced expression and cleavage of 
caspase-11, but there was no difference among PTPN22-deficient, 
PTPN22-WT, and PTPN22-619W–expressing cells (Supplemental 
Figure 2E), ruling out that the observed effects on IL-1β secretion 
might result from changes in caspase-11 activity. Taken together, 
our data indicate that loss of PTPN22 results in a reduction in 
mature IL-1β release, without reducing the expression of pro–IL-1β 
or other inflammasome components.
NLRC4- and AIM2-mediated IL-1β secretion is not affected upon 
loss of PTPN22. As other pattern recognition receptors (PRRs) 
besides NLRP3 can form inflammasome complexes, we next 
addressed whether PTPN22 is also involved in mature IL-1β 
secretion upon activation of the NLRC4 or AIM2 inflammasome. 
Flagellin (a NLRC4 ligand; ref. 5) and dsDNA (inducing AIM2 acti-
vation; ref. 31) transfection of THP-1 cells resulted in IL-1β secre-
tion, without a significant difference between PTPN22-expressing 
and PTPN22-deficient cells. Also, LDH release and TNF secretion 
To confirm that the reduction in cleaved IL-1β affects bioac-
tive IL-1, we cultured D10.G4.1 cells, which respond to the pres-
ence of bioactive IL-1 with proliferation, in the presence of cell 
culture supernatant from MSU-treated THP-1 cells or BMDCs. 
In the presence of supernatant from MSU-treated WT BMDCs 
or THP-1 cells expressing control shRNA, the cells proliferated, 
and this was blocked upon addition of an IL-1 receptor antagonist 
(Supplemental Figure 2B and data not shown). With superna-
tants from Ptpn22–/– BMDCs or THP-1 cells expressing PTPN22- 
specific shRNA, proliferation was reduced (Supplemental Figure 
2B), indicating that differences in IL-1β measurements in ELISA 
and Western blot analysis are specific for bioactive IL-1β. Further, 
this demonstrates that the reduction in IL-1β upon loss of PTPN22 
has profound consequences for the proliferation of IL-1–depen-
dent cells, suggesting the physiological relevance of our findings.
In MDP-treated THP-1 cells, loss of PTPN22 resulted in 
reduced expression of pro-IL1B mRNA after 24 hours, likely due 
to the effect of PTPN22 on MDP-induced signaling in monocytic 
cells (22), while in MM6 cells and BMDCs, loss of PTPN22 did not 
affect MDP-induced IL1B/Il1b or NLRP3/Nlrp3 mRNA expression 
(Supplemental Figure 2C). As PTPN22 has been implicated in 
affecting LPS-mediated TLR4 responses (23), we next addressed 
whether loss or altered function of PTPN22 might affect LPS- 
induced NLRP3/IL-1β expression. When we used upLPS as a prim-
ing agent, loss of PTPN22 had no effect on IL1B or NLRP3 mRNA 
expression (Supplemental Figure 2C). upLPS efficiently induced 
IL-1β and NLRP3 mRNA/protein, and there was no difference 
observed among WT, Ptpn22–/–, and 619W BMDCs (Supplemen-
tal Figure 2, C–E). BioGPS datasets (26) suggest a reduction in 
Figure 3. PTPN22 does not affect NLRC4- or AIM2-mediated IL-1β secretion. THP-1 cells expressing control or PTPN22-targeting shRNA were pretreated 
for 12 hours with upLPS before transfection with flagellin (Flag) or dsDNA and analyzed for (A) IL-1β, IL-6, LDH, and TNF release by ELISA and (B) caspase-1 
cleavage and IL-1β maturation by Western blot. Data are representative of 4 independent experiments. *P < 0.05, Newman-Keuls post hoc test.
Downloaded from http://www.jci.org on July 18, 2016.   http://dx.doi.org/10.1172/JCI83669
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 7 8 7jci.org   Volume 126   Number 5   May 2016
tion (Figure 4B and Supplemental Figure 3A, left). This was also 
observed in THP-1 cells treated with other NLRP3 inflammasome 
activators, namely TiO2, SiO2, and ATP (Figure 4C). On the other 
hand, PTPN22 did not interact with NLRC4 or AIM2, regardless 
of their activation status (Figure 4, D and E).
To confirm this observation, we immunoprecipitated NLRP3 
from the respective cell lysates and immunoblotted for PTPN22. 
Again, upon MDP or MSU treatment, we detected PTPN22 in 
NLRP3 immunoprecipitates from human THP-1 and MM6 cells, 
as well as from mouse BMDCs (Figure 5, A and B), while NLRP3 
did not interact with the related phosphatase PTPN2 (Figure 5A 
and Supplemental Figure 3B), indicating a specific interaction 
between PTPN22 and NLRP3. The direct interaction between 
NLRP3 and PTPN22 prompted us to address whether a com-
ponent of the NLRP3 inflammasome might be tyrosine phos-
phorylated, since PTPN22 regulates its substrates via tyrosine 
dephosphorylation. Given the direct interaction between NLRP3 
and PTPN22, we first probed the NLRP3 precipitates from THP-1 
monocytes, MM6 macrophages, or primary mouse BMDCs 
treated with either MSU or MDP for phosphotyrosine (pTyr). 
We detected a pTyr band in the precipitates at the height of full-
remained unchanged, while IL-6 was again increased (Figure 3). 
Correspondingly, loss of PTPN22 did not affect levels of cleaved 
caspase-1 or mature IL-1β in cell lysates or cell supernatants from 
THP-1 cells treated with either flagellin or dsDNA (Figure 3). This 
indicates that PTPN22 specifically modulates NLRP3-mediated 
inflammasome activation but does not affect activity of NLRC4 or 
AIM2 inflammasomes.
NLRP3 interacts with PTPN22 and is regulated by tyrosine 
phosphorylation. Having shown that PTPN22 specifically regu-
lates NLRP3 dependent IL-1β secretion, we next investigated the 
possible molecular mechanism underlying this effect. We first 
investigated whether PTPN22 interacts directly with the NLRP3 
inflammasome complex. Immunoprecipitation of PTPN22 and 
subsequent immunoblotting for NLRP3 revealed a direct interac-
tion between PTPN22 and NLRP3 that was enhanced upon MDP 
or MSU treatment in human THP-1 and MM6 cells, as well as in 
primary mouse BMDCs (Figure 4, A and B). The same was true for 
the altered-function PTPN22 (PTPN22-619W) variant in BMDCs. 
Basal interaction of PTPN22-619W with NLRP3 appeared to be 
slightly increased when compared with WT PTPN22, and also 
in these cells, inflammasome activation increased the interac-
Figure 4. PTPN22 interacts with NLRP3 upon inflammasome activation. THP-1 cells, MM6 cells, and BMDCs were treated with upLPS for 12 hours prior 
to activation with MDP (100 ng/ml, 24 hours), MSU (100 ng/ml, 6 hours), TiO2 (150 ng/ml, 24 hours), SiO2 (150 ng/ml, 24 hours), ATP (2 mM, 30 minutes), 
dsDNA, or flagellin, as indicated. (A and C) PTPN22 was precipitated from THP-1 or MM6 lysates and analyzed by Western blot for coprecipitated NLRP3. 
(B) PTPN22 was precipitated from BMDCs and analyzed for NLRP3. (D) PTPN22 was precipitated from dsDNA-treated THP-1 cells or BMDCs and analyzed 
by Western blot for coprecipitation of AIM2. (E) PTPN22 was precipitated from dsDNA-treated THP-1 cells or BMDCs and analyzed by Western blot for 
coprecipitation of NLRC4. Data are representative of 1 of 3–5 independent experiments.
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length NLRP3 in all of our tested cell types (130 kDa in human 
cells, 120 kDa in mouse tissue; Figure 5 and Supplemental Fig-
ure 3A). Of note, this pTyr band was increased upon loss of 
PTPN22, while it was reduced with the presence of the PTPN22-
619W variant (Figure 5B). While in nonactivated cells, PTPN22- 
NLRP3 interaction was low or absent (Figures 4 and 5), activa-
tion resulted in increased interaction and efficient dephospho-
rylation of NLRP3 (Figure 5 and Supplemental Figure 3A). Since 
it has recently been reported that inflammasome activation is 
dependent on ASC phosphorylation, we further studied whether 
loss of PTPN22 additionally affects ASC tyrosine phosphory-
lation in mouse BMDCs. Precipitation of ASC and subsequent 
probing for pTyr revealed tyrosine phosphorylation of ASC upon 
inflammasome activation, but there was no detectable differ-
ence between WT and Ptpn22–/– cells (Supplemental Figure 4).
In human primary peripheral blood mononuclear cells 
(PBMCs), we also detected a physical interaction between 
PTPN22 and NLRP3 and observed tyrosine phosphorylation of 
NLRP3. Upon NLRP3 inflammasome activation, as measured 
by IL-1β secretion and cleavage of caspase-1 and IL-1β (data not 
shown), NLRP3 tyrosine phosphorylation was decreased (Figure 
5D). Using a semiquantitative approach, we found that roughly 
60%–80% of NLRP3 was tyrosine phosphorylated in nonactivated 
cells, and the level dropped to below 10% upon MSU treatment 
(Figure 5E). Upon loss of PTPN22, basal NLRP3 phosphorylation 
was not altered, but upon inflammasome activation, phosphoryla-
Figure 5. NLRP3 is tyrosine phosphorylated. THP-1 and MM6 cells (A and C), BMDCs (B), and PBMCs (D) were treated with upLPS for 12 hours prior to 
activation with MDP (100 ng/ml, 24 hours), MSU (100 ng/ml, 6 hours), TiO2 (150 ng/ml, 24 hours), SiO2 (150 ng/ml, 24 hours), ATP (2 mM, 30 minutes), 
dsDNA, or flagellin, as indicated. NLRP3 was precipitated from cell lysates, and precipitates were analyzed for tyrosine phosphorylation, coprecipitated 
PTPN22, or coprecipitated PTPN2. (D) PTPN22 was precipitated in addition to NLRP3 and analyzed for coprecipitated NLRP3. (E) Amounts of NLRP3 and 
pTyr in NLRP3 precipitates were quantified using standard curves for NLRP3 and a pTyr peptide. The graph below the representative Western blots shows 
statistical analysis of densitometry. ND, not detected. Left and right blots in E were run on the same gel, but were discontinuous. Numbers below the blots 
in D show the amount of loaded NLRP3 or pTyr peptide (left) and measured amounts (right), respectively. The pound symbol (#) marks blots where the 
130-kDa and 120-kDa forms of NLRP3 are not completely separated and appear as single bands. Data shown are from 1 of 3–5 independent experiments. 
*P < 0.05, **P < 0.01, Student’s t test with Bonferroni correction.
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tion increased to almost 100% (Figure 5E). In cells expressing the 
autoimmunity-associated PTPN22 variant, NLRP3 phosphoryla-
tion was reduced already in the basal state and completely absent 
upon MSU treatment (Figure 5E), indicating a gain of function of 
this variant with respect to NLRP3 dephosphorylation.
These data indicate that PTPN22 regulates the activity of 
the NLRP3 inflammasome by interfering with NLRP3 tyrosine 
phosphorylation. NLRP3 is thereby phosphorylated at the basal 
state, and activation is accompanied by decreased phosphory-
lation. When PTPN22 is missing, NLRP3 phosphorylation, how-
ever, increases upon its activation. In this way, PTPN22 dephos-
phorylates NLRP3 promoting sustained activation of the NLRP3 
inflammasome. These findings reveal a mechanism regulating the 
NLRP3 inflammasome.
PTPN22 targets NLRP3 at tyrosine residue Tyr861. To fur-
ther confirm our findings, we transfected the THP-1 cells with 
PTPN22, NLRP3, or PTPN22 and NLRP3 knockdown constructs. 
The NLRP3 pTyr band was enhanced in PTPN22-deficient cells 
Figure 6. NLRP3 is tyrosine phosphorylated at Tyr861. (A) THP-1 cells expressing control or PTPN22-targeting shRNA were treated with control or 
NLRP3-targeting siRNA constructs and incubated for 12 hours with upLPS before activation with MSU (6 hours). NLRP3 or PTPN22 was precipitated from 
the cell lysates and analyzed for tyrosine phosphorylation and PTPN22 coprecipitation or NLRP3 coprecipitation, respectively. (B) Purified NLRP3 was 
incubated in phosphatase buffer for 60 minutes in the presence or absence of purified WT-PTPN22 (WT), altered-function PTPN22 (619W), loss-of-function 
PTPN22 (263Q), or purified PTPN2. (C) Multiple sequence alignment of NLRP3 sequences from the indicated species using FASTA.2 (http://www.ebi.ac.uk) 
reveals conservation of the tyrosine at position 861. (D) HEK293T cells were transfected with WT NLRP3 or a NLRP3 construct where Tyr861 was replaced 
by a phenylalanine (Y>F). NLRP3 was immunoprecipitated and analyzed for the presence of pTyr. Lys, lysates. (E and F) Nlrp3–/– BMDCs were left nontrans-
fected or transfected with WT NLRP3; Y>F NLRP3; or NLRP3 where Tyr858 was replaced with a glutamine to mimic constitutive phosphorylation (Y>E) or 
by an alanine (control to glutamine substitution [Y>A]) and activated with MSU. Lysates (E) and supernatants (F) were analyzed for the indicated proteins. 
(G) BMDCs were derived from ASC-, caspase-1–, NLRP3-, or PTPN22-deficient mice or mice expressing the autoimmunity-associated PTPN22 variant (619W); 
pretreated for 12 hours with upLPS; and activated with MSU. NLRP3 was immunoprecipitated and analyzed for pTyr and PTPN22. All data are representative 
of 1 of 3–5 independent experiments. Numbers below the blots show results of densitometry.
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tyrosine phosphorylation, which was not changed upon coincu-
bation with PTPN2 or with loss-of-function PTPN22-263Q. In 
NLRP3 samples incubated with PTPN22-containing precipitates, 
however, tyrosine phosphorylation was strongly reduced after 60 
minutes (Figure 6B). Consistent with a gain of function, incuba-
tion with PTPN22-620W resulted in faster and more efficient 
NLRP3 dephosphorylation (Figure 6B).
We then studied which tyrosine residue within the NLRP3 pro-
tein might be targeted by PTPN22. In humans, NLRP3 exists in 
several different splice variants, including a full-length (130-kDa) 
form and an intermediate (120-kDa) form that lacks amino acids 
720–776 and 834–890 (34). Interestingly, only one tyrosine resi-
due is located within this sequence at position 861. Of note, this 
residue is conserved among mammals (Figure 6C). As we only 
detected tyrosine phosphorylation in the full-length but not in the 
but absent in immunoprecipitates from THP-1 cells treated with 
NLRP3-targeting siRNA (Figure 6A), indicative of the NLRP3 
specificity of the pTyr band. To further confirm that PTPN22 
directly dephosphorylates NLRP3, we used a cell-free in vitro sys-
tem (32). We collected phosphorylated NLRP3 from NLRP3-trans-
fected HEK293T cells and PTPN22 from THP-1 cells by immu-
noprecipitation. As controls, we used those immunoprecipitates 
from THP-1 cells expressing PTPN22 shRNA in which we did not 
detect PTPN22; and immunoprecipitates from HEK cells express-
ing either the autoimmunity-associated variant (620W), a loss-of-
function PTPN22 variant (263Q), or the related phosphatase 
PTPN2 (Figure 6B). In the 263Q variant, a crucial arginine in the 
catalytic domain is mutated to a Q residue, resulting in a complete 
loss of phosphatase activity (33). In NLRP3 samples incubated 
with control immunoprecipitates, we found readily detectable 
Figure 7. Loss of PTPN22 enhances colitis, while presence of the 619W variant is protective. Acute colitis was induced in female WT, Ptpn22–/–, or 
PTPN22-619W (619W) mice by administration of 2.5% DSS for 7 days. (A) Weight development, representative images from colonoscopy, MEICS score 
analysis, colon length, spleen weight, and MPO activity. (B) H&E staining from the distal colon and analysis of epithelial damage and infiltration. All 
data are representative of 1 of 2 independent experiments with 4–6 mice per group each (n = 4–6). Each dot represents one mouse. *P < 0.05, **P < 0.01, 
Mann-Whitney U test with Bonferroni correction. Original magnification (H&E), ×10.
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the presence of the 619W PTPN22 variant resulted in enhanced 
NLRP3-mediated IL-1β and caspase-1 activation when the WT 
NLRP3 construct was used; the presence of the 623Q loss-of-
function PTPN22 variant had the opposite effect (Supplemental 
Figure 5), indicating that PTPN22-619W acts as a gain-of-func-
tion variant. On the other hand, neither of the variants affected 
inflammasome activation in the Y>F or Y>E NLRP3 constructs 
(Supplemental Figure 5), showing that the effects on NLRP3 are 
dependent on NLRP3 phosphorylation at Tyr859. This indicates 
that PTPN22 enhances NLRP3 activation through dephosphoryla-
tion of Tyr861/Tyr859. Taken together, these results suggest that 
phosphorylation of NLRP3 at Tyr861 (Tyr859 in the mouse) nega-
tively regulates NLRP3 activation.
ASC is necessary for PTPN22-NLRP3 interaction. As a next step, 
we addressed whether a functional inflammasome is necessary for 
PTPN22-NLRP3 interaction under physiological conditions. There-
fore, we differentiated primary BMDCs from caspase-1–, ASC-, 
or NLRP3-deficient mice; stimulated them with MSU to induce 
inflammasome assembly; and immunoprecipitated NLRP3 from 
the respective lysates. Surprisingly, loss of the adaptor molecule ASC 
abrogated the direct interaction between NLRP3 and PTPN22, and 
resulted in enhanced levels of NLRP3 phosphorylation in NLRP3 
precipitates. In contrast, in NLRP3 immunoprecipitates from cas-
pase-1–deficient BMDCs, there was detectable tyrosine phosphory-
lation of NLRP3, which disappeared following treatment with MSU, 
and this was accompanied by an enhanced NLRP3-PTPN22 inter-
action. This indicates that caspase-1 activation is dispensable for 
the observed effects of PTPN22 on NLRP3 phosphorylation (Figure 
intermediate form of NLRP3, we hypothesized that the phospho-
rylated residue might be the tyrosine at position 861 (Tyr861). To 
test this hypothesis, we transfected HEK293T cells with either a 
WT NLRP3 vector (WT-NLRP3) or a target mutated form, where 
Tyr861 was replaced with a phenylalanine residue (Y>F-NLRP3). 
While tyrosine phosphorylation was detected in WT-NLRP3, this 
band was completely absent in the Y>F-NLRP3 construct (Fig-
ure 6D). This confirms our previous findings and indicates that 
PTPN22 dephosphorylates NLRP3 at Tyr861.
NLRP3 phosphorylation negatively regulates NLRP3 activation. 
To test the functional consequence of the absence of NLRP3 phos-
phorylation, we introduced WT-NLRP3, Y>F-NLRP3, Y>E (mim-
icking constant phosphorylation of Tyr859 [the mouse ortholog 
of human Tyr861]), or Y>A (negative control for Y>E) vectors into 
BMDCs prior to inflammasome activation. To rule out interaction 
of the constructs with endogenous NLRP3, we used Nlrp3–/– or 
Nlrp3 Ptpn22 double-deficient cells for this study. Transfection 
with WT-NLRP3 resulted in moderate inflammasome activation 
and IL-1β secretion following MSU treatment, which was reduced 
in Ptpn22–/– cells. When we transfected the cells with the Y>F- 
NLRP3 construct, where Tyr859 phosphorylation is not possible, 
NLRP3 activation was increased as indicated by elevated cas-
pase-1 and IL-1β cleavage, and loss of PTPN22 was no longer able 
to reduce NLRP3 activation (Figure 6, E and F). Mimicking con-
stant phosphorylation of NLRP3 using the Y>E construct, on the 
other hand, resulted in abrogation of NLRP3 activity, while muta-
tion to alanine (Y>A; a control for glutamate substitution) had the 
same effect as the Y>F substitution (Figure 6, E and F). Of note, 
Figure 8. Reduced infiltration of granulocytes in the inflamed colon of Ptpn22–/– and Nlrp3–/– mice. Acute colitis was induced in female WT, Ptpn22–/–, 
or Nlrp3–/– mice by administration of 2.5% DSS for 7 days. Immunohistochemistry of the distal colon stained for CD3+ T cells (A) and Gr1+ granulocytes (B). 
Statistical analysis of infiltrating cells is shown in C. Data are representative of 1 of 2 independent experiments with 4–6 mice per group each (n = 4–6). 
Each dot represents 1 mouse. *P < 0.05, Mann-Whitney U test with Bonferroni correction. Original magnification (IHC), ×10.
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This might explain the observed changes in the MPO assay (Figure 
8). Of note, PTPN22-619W mice also show decreased MPO levels 
when compared with WT animals (Figure 7A), most likely due to 
overall reduced inflammation and generally reduced infiltration 
of inflammatory cells into the intestine (Figure 7B). Further, when 
using NLRP3-deficient (Nlrp3–/–) mice, we observed a phenotype 
similar to that in Ptpn22–/– mice: loss of NLRP3 resulted in aggra-
vated weight loss, enhanced colitis score, pronounced shortening of 
the colon, and a reduction in MPO levels (Figure 9), accompanied 
by decreased granulocyte but enhanced T cell infiltration (Figure 
8). Similar results were obtained in bone marrow chimeras, wherein 
NLRP3 was absent only in in hematopoietic cells but normally 
expressed in stromal cells (Supplemental Figure 6). This is in line 
with several previous reports indicating enhanced DSS-induced 
colitis in Nlrp3–/– mice (10, 35). Nevertheless, the colitis phenotype 
in Nlrp3–/– mice is controversial (10, 11, 35).
NLRP3 phosphorylation in the mouse colon is reduced upon DSS 
treatment. To analyze whether tyrosine phosphorylation of NLRP3 
and inflammasome activation play a role in the inflamed intestine, 
we isolated protein from colon tissue of DSS- and water-treated ani-
mals. Western blot analysis showed that DSS administration induced 
cleavage of caspase-1 and IL-1β, as well as IL-18 cleavage (Figure 10A 
and Supplemental Figure 7A). We additionally immunoprecipitated 
NLRP3 from homogenized colon specimens and found basal NLRP3 
6G). Further, we again found that PTPN22-619W constitutively 
interacted with NLRP3, and this interaction was further enhanced 
upon MSU stimulation (Figure 6G). Consistently, phosphorylation 
of NLRP3 was lower in cells expressing PTPN22-619W when com-
pared with cells expressing WT PTPN22 (Figure 6G).
Loss of PTPN22 results in aggravated DSS-mediated intestinal 
inflammation. To test the in vivo relevance of PTPN22 in intesti-
nal inflammation, we treated WT, Ptpn22–/–, and PTPN22-619W 
mice with DSS for 8 days to induce acute intestinal inflammation. 
As reported previously (23), loss of PTPN22 resulted in aggravated 
intestinal inflammation as demonstrated by pronounced weight 
loss, increased colitis score, and pronounced shortening of the colon, 
while the presence of PTPN22-619W had a protective effect (Fig-
ure 7A). Interestingly, DSS-induced increases in myeloperoxidase 
(MPO) levels — an indicator of infiltration/activation of neutrophilic 
granulocytes — which were clearly observable in WT animals, were 
less pronounced in Ptpn22–/– animals (Figure 7A). In H&E-stained 
sections from the terminal colon, Ptpn22–/– mice harbored increased 
inflammatory infiltrates upon DSS treatment, while DSS-induced 
epithelial damage was not altered (Figure 7B). PTPN22-619W mice, 
on the other hand, showed reduced infiltration and epithelial dam-
age (Figure 7B). While infiltration of CD3+ cells — indicative of T 
lymphocytes — was enhanced in Ptpn22–/– mice, we found reduced 
numbers of Gr1+ cells, indicative of reduced granulocyte infiltration. 
Figure 9. Loss of NLRP3 results in 
pronounced colitis in our housing 
conditions. Acute colitis was 
induced in female WT, Ptpn22–/–, 
or Nlrp3–/– mice by administration 
of 2.5% DSS for 7 days. (A) Weight 
development, (B) MPO activity, and 
(C) colon length. (D) H&E staining 
from the distal colon and (E) anal-
ysis of epithelial damage and infil-
tration. All data are representative 
of 1 of 2 independent experiments 
with 4–6 mice per group each  
(n = 4–6). Each dot represents 
1 mouse. *P < 0.05, **P < 0.01, 
Mann-Whitney U test with Bonfer-
roni correction. Original magnifica-
tion (H&E and IHC), ×10.
Downloaded from http://www.jci.org on July 18, 2016.   http://dx.doi.org/10.1172/JCI83669
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 7 9 3jci.org   Volume 126   Number 5   May 2016
although IL-1β cleavage was reduced (Figure 10A). In contrast, and 
consistent with a gain of function of the 619W variant, PTPN22-
619W animals displayed increased levels of IL-1β and caspase-1 
cleavage (Supplemental Figure 7C). To address in greater detail 
which compartments of the intestinal wall are responsible for cas-
pase-1 cleavage and IL-1β/IL-18 activation, we separated epithelial 
cells and lamina propria to study inflammasome activation in these 
two fractions separately. Interestingly, caspase-1, IL-1β, and IL-18 
cleavage was reduced in the lamina propria but not in the epithelial 
phosphorylation, which was reduced upon DSS administration (Fig-
ure 10B and Supplemental Figure 7A). In samples from Ptpn22–/– ani-
mals, however, DSS treatment clearly enhanced NLRP3 tyrosine 
phosphorylation, while the presence of the PTPN22-619W variant 
further reduced it (Figure 10B and Supplemental Figure 7, A and B).
PTPN22 affects NLRP3 activation only in the lamina propria, 
but not in epithelial cells. In whole colon specimens from Ptpn22–/– 
mice, we surprisingly detected only minor changes in DSS-induced 
caspase-1 or IL-18 activation when compared with WT animals, 
Figure 10. Reduced inflammasome activation in the lamina propria of Ptpn22–/– mice. Colitis was induced in WT and Ptpn22–/– littermates by adminis-
tration of 2.5% DSS for 7 days. (A) Colon specimens were analyzed for caspase-1, IL-1β, and IL-18 by Western blot. (B) NLRP3 was immunoprecipitated from 
whole colon specimens and analyzed for tyrosine phosphorylation and interaction with PTPN22. (C) Intestinal epithelial cell (IEC) fraction and lamina pro-
pria (LP) were analyzed for caspase-1, IL-1β, and IL-18 by Western blot. (D) Lamina propria cells and epithelial cells were analyzed for Ptpn22 mRNA levels 
normalized to Actb. (E) NLRP3 was precipitated from lamina propria or epithelial cells and analyzed for pTyr and PTPN22. Numbers below the Western blot 
images show results of densitometry, and each lane represents one mouse.
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Increased IL-1β secretion in IBD patients carrying an altered-
function variant of PTPN22. Knockdown or knockout approaches 
only partially reflect the functional impact of disease-associ-
ated variants in the human setting. As a next step, we therefore 
assessed the impact of the autoimmunity-associated PTPN22 
variant rs2476601 (12) in inflammasome activation. To this end, 
we used intestinal biopsies and serum from CD patients either 
homozygous for the major (G), heterozygous, or homozygous for 
the minor (A) PTPN22 allele. Of note, the minor (A) variant results 
in an altered-function protein product, enhancing PTPN22’s in 
vitro dephosphorylation capacity (17). The presence of rs2476601 
confers protection from CD (12) but increases the risk for other 
autoimmune diseases (14, 15). Since the A allele is rare, specimens 
from only three patients with the AA genotype were available, 
and intestinal biopsies were obtained from only two of them. The 
presence of the A allele did not change PTPN22 or NLRP3 mRNA 
expression (Figure 12A), but both IL1B mRNA expression and 
secretion of IL-1β were enhanced in carriers of the A allele (Fig-
ure 12, A and B). Although the homozygous carriers of the A allele 
showed the greatest expression of IL1B mRNA, and one of them 
had extremely high serum IL-1β levels, the number of homozygous 
patients was far too low to draw conclusions about a possible gene 
dose effect. In monocyte-derived dendritic cells (mono-DCs) dif-
ferentiated from the blood of IBD patients heterozygous for the 
A allele and treated for 6 hours with MSU, we detected increased 
levels of cleaved caspase-1 and IL-1β when compared with mono-
cell compartment in Ptpn22–/– mice (Figure 10C and Supplemental 
Figure 7D). Further, we found Ptpn22 mRNA expression only in the 
lamina propria, but not in the epithelial cell fraction (Figure 10D). 
In the inflamed intestine, intestinal epithelial cells are the main 
producers of IL-18, which might explain why overall IL-18 secretion 
remained unchanged in inflamed colon tissue from Ptpn22–/– mice.
As a next step we addressed NLRP3 tyrosine phosphorylation 
within the intestinal epithelial cell compartment and the lamina 
propria. In WT animals, we found basal NLRP3 tyrosine phospho-
rylation in both compartments. Consistent with our finding in the 
whole colon, DSS treatment reduced NLRP3 phosphorylation in 
the lamina propria and epithelial cells in WT mice (Figure 10E). In 
Ptpn22–/– mice, DSS challenge increased NLRP3 phosphorylation 
in the lamina propria but not in the epithelial cell fraction, where 
DSS treatment resulted in reduced NLRP3 phosphorylation to a 
level similar to that in WT animals (Figure 10E).
Loss of PTPN22 reduces IL-1β–mediated peritonitis. To further 
test the physiological in vivo relevance of PTPN22-mediated 
reduction of IL-1β secretion, we induced MSU-mediated peri-
tonitis in WT, Ptpn22–/–, PTPN22-619W, and Nlrp3–/– mice. In 
this model, IL-1β plays a predominant role in the recruitment of 
neutrophils (36). Consistent with a reduction in NLRP3-medi-
ated inflammasome activation, peritoneal IL-1β levels, as well as 
recruitment of neutrophils (but not of T cells), were reduced in 
Ptpn22–/– animals, while they were increased in mice expressing 
the PTPN22-619W variant (Figure 11).
Figure 11. Reduced peritonitis in 
Ptpn22–/– mice. Acute peritonitis 
was induced in WT and Ptpn22–/– 
mice by injection of 1.8 mg MSU for 
6 hours. (A) Representative images 
of flow cytometry, and quanti-
tation of infiltrating neutrophils 
(B) and T cells (C), as well as IL-1β 
levels (D) in peritoneal lavages are 
shown. *P < 0.05, **P < 0.01,  
***P < 0.001, Mann-Whitney U 
test. Data are representative of 1 
of 3 independent experiments with 
3–5 mice/group.
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matory insults (10). Here we describe a mechanism by which the 
NLRP3 inflammasome is regulated via tyrosine phosphoryla-
tion on Tyr861, a process controlled by PTPN22. Interestingly, 
a naturally occurring NLRP3 variant resulting in a substitution 
of Tyr861 by a Cys residue causes chronic infantile neurologic 
cutaneous and articular syndrome (CINCA) (37), a severe form 
of spontaneous inflammatory disease. This is consistent with our 
findings using an NLRP3 construct in which Tyr861 is replaced 
with a phenylalanine residue, which resulted in enhanced 
NLRP3 activity. Loss of PTPN22 and subsequently increased 
phosphorylation of NLRP3 at Tyr861, on the other hand, resulted 
in decreased NLRP3 activation and reduced IL-1β secretion. We 
demonstrate that PTPN22 directly interacts with NLRP3 and is 
able to dephosphorylate NLRP3. In a mouse model of colitis as 
well as in tissue and serum samples from CD patients, we con-
firmed our in vitro findings and demonstrated the in vivo rele-
vance of our observations.
DCs from IBD patients or healthy controls homozygous for the G 
allele (Figure 12C). To address whether changes in inflammasome 
activation might result from changes in LPS-mediated induction 
of either NLRP3 or IL1B, we further analyzed mRNA expression 
in upLPS-treated mono-DCs. Mono-DCs from patients heterozy-
gous for the A allele expressed enhanced levels of IL1B mRNA 
when treated with upLPS, but there was no difference in NLRP3 
mRNA expression (Figure 12D). This indicates that increased 
function of PTPN22 promotes NLRP3 inflammasome activation, 
likely due to more efficient dephosphorylation. These observa-
tions indicate the relevance of our findings for human physiology.
Discussion
Negative regulation of NLRP3 activity is of crucial importance to 
control inflammatory responses. However, physiological inflam-
masome activation is needed for an effective host response and 
induction of repair mechanisms upon cellular injury and inflam-
Figure 12. The presence of PTPN22 gain-of-function variant results in increased IL-1β levels. Intestinal biopsies and serum samples from CD patients 
homozygous for the major (G) variant or heterozygous or homozygous for the minor (A) PTPN22 variant in SNP rs2476601 were analyzed for (A) PTPN22, 
NLRP3, or IL1B mRNA levels (normalized to ACTB); and (B) serum levels of IL-1β. Monocyte-derived dendritic cells from healthy controls (HC), CD patients 
homozygous for the G variant (GG), or CD patients heterozygous for the A variant (GA) were (C) primed for 16 hours with upLPS before activation with MSU 
for 6 hours prior to analysis for caspase-1 and IL-1β by Western blot; or (D) left untreated or primed for 16 hours with upLPS before analysis of PTPN22, 
NLRP3, or IL1B mRNA expression. Data are shown as values relative to nontreated controls and normalized to ACTB. Each dot/lane represents an individual 
patient; *P < 0.05, **P < 0.001 (Mann-Whitney U test with Bonferroni correction). Numbers below the Western blot images show results of densitometry.
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on the presence of the inflammasome adaptor ASC within cells. 
This might be due to the more complex situation within the cell, 
where ASC might be necessary to stabilize the interaction between 
NLRP3 and PTPN22. As we found that PTPN22 more efficiently 
interacts with NLRP3 upon inflammasome induction, ASC might 
play a role in promoting or stabilizing NLRP3-PTPN22 interac-
tion and subsequent reduction of NLRP3 activity. This would also 
explain why inflammasome activation is not fully abrogated upon 
loss of PTPN22. This critical role for ASC in controlling inflam-
masome activity is in line with a previous report from Hara et al. 
that showed that ASC phosphorylation is important for controlling 
inflammasome assembly (4).
While NLRP3 tyrosine phosphorylation is abrogated 
upon inflammasome activation in PTPN22-competent cells, 
it is enhanced in response to inflammasome activation in 
PTPN22-deficient cells. NLRP3 phosphorylation is likely induced 
by a so-far-unknown kinase that inhibits aberrant inflammasome 
activity. If PTPN22 — or, in the case of cells that do not express 
PTPN22, another protein tyrosine phosphatase — is sufficiently 
activated, NLRP3 tyrosine phosphorylation is limited, resulting in 
sustained NLRP3 activation.
Several additional mechanisms, including autophagy and 
noncanonical activation of NLRP3, have been implicated in con-
trolling IL-1β secretion. PTPN22 has been described to affect 
LPS-induced responses (27), as well as type I IFN responses (28). 
Both mechanisms are reported to influence caspase-11 activation, 
which in turn mediates noncanonical IL-1β secretion/NLRP3 acti-
vation (30). Since we did not detect changes in caspase-11 activ-
ity upon loss of PTPN22, we assume that noncanonical inflam-
masome activation is not affected by PTPN22. Autophagy limits 
IL-1β secretion by targeting pro–IL-1β for degradation (41). How-
ever, the function of autophagy in IL-1β secretion is controversial, 
as a study by Dupont et al. demonstrated a role for autophagy in 
unconventional protein secretion of IL-1β (42). We have previ-
ously shown that loss of PTPN22 results in enhanced autophagy 
(22); hence, we cannot exclude that loss of PTPN22 additionally 
affects IL-1β secretion via an indirect mechanism.
Although we show that PTPN22 is necessary for efficient 
NLRP3 activation in hematopoietic cells, some cell types, includ-
ing intestinal epithelial cells (43) and fibroblasts (44), express 
NLRP3 and show efficient NLRP3 activation, although PTPN22 
expression is low or even absent in these cells (45). Therefore, we 
speculate that other phosphatases might also be able to dephos-
phorylate NLRP3 in these cell types.
In line with previous reports (23), PTPN22-deficient animals 
experienced aggravated colitis, while PTPN2-619W mice showed 
the opposite phenotype. Interestingly, levels of granulocyte infil-
tration and MPO activity were reduced in Ptpn22–/– and Nlrp3–/– 
mice, while all other addressed colitis parameters were enhanced 
or unchanged. As IL-1β is important for the attraction of gran-
ulocytes into the inflamed colon (46), this is consistent with the 
decreased IL-1β levels observed in the lamina propria of Ptpn22–/– 
mice. Since MPO not only plays a role in tissue destruction, but is 
also involved in defense against intracellular bacteria and in limit-
ing T cell–mediated immunity (47), this reduction might actually 
contribute to disease progression in Ptpn22–/– animals. Further, the 
limiting role of MPO on T cell biology might explain the increased 
The altered-function variant in PTPN22 is associated with 
enhanced susceptibility to inflammatory diseases, including RA, 
T1D, and SLE (13–15), where increased levels of IL-1β are observed 
(16). Of interest, the same variant protects from CD (12). In the lit-
erature, conflicting data exist on whether the autoimmunity-asso-
ciated PTPN22 variant results in enhanced or decreased PTPN22 
function. While in vitro data showed that the variant results in 
enhanced phosphatase activity (17), in vivo data indicated that the 
variant has effects similar to those of the knockout in terms of T 
cell regulation (25, 38, 39). This discrepancy has been explained by 
altered substrate specificity of the 620W PTPN22 variant. From our 
data, we conclude that the autoimmunity-associated variant results 
clearly in a gain of function in terms of NLRP3 activation. Since we 
found slightly increased interaction of PTPN22-619W with NLRP3, 
we conclude that the effects observed here might be the result of 
both enhanced phosphatase activity and increased substrate inter-
action. In terms of type I IFN expression and IL-6 secretion, how-
ever, the presence of the 619W variant results in a loss-of-function 
phenotype. Since the 619W variant in PTPN22 has been suggested 
to affect substrate specificity or substrate binding capacity (25), we 
believe that the gain-of-function phenotype regarding NLRP3 acti-
vation and the concomitant loss-of-function phenotype regarding 
type I IFN responses might reflect shifted PTPN22 binding to the 
respective targets (i.e., equal or slightly increased binding capac-
ity to NLRP3 but reduced binding capacity to molecules involved 
in type I IFN responses; ref. 25). Given the role described here for 
PTPN22 in facilitating inflammasome activation, the controversial 
effect on disease susceptibility in intestinal inflammation and other 
inflammatory disorders can be explained when considering that 
NLRP3 activation is involved in wound healing and host defense 
against invading bacteria in the intestine. In mouse colitis, mye-
loid cell–derived IL-1β prevents epithelial disruption and promotes 
wound healing and repair (40). In the more sterile settings of RA 
and SLE, however, exacerbated NLRP3 activity that might — at least 
in part — result from increased PTPN22 activity in variant carriers 
leads to enhanced inflammation. On this background, it is obvious 
that Ptpn22–/– animals react less to MSU-induced peritonitis, while 
they experience aggravated colitis: in the intestine, inflammasome 
activation is important to protect against invading pathogens and to 
prevent epithelial disruption/induce epithelial reconstitution (40), 
and reduction of inflammasome activity results in enhanced colitis 
severity (10, 11, 35). Nevertheless, there is controversy regarding the 
role of NLRP3 in intestinal inflammation, with some reports show-
ing that loss of NLRP3 and subsequent impaired inflammasome 
activation can protect from colitis (9). This suggests that the role 
of the NLRP3 inflammasome in colitis might depend on environ-
mental factors. In the setting of sterile MSU-induced peritonitis, 
inflammasome activation is undoubtedly the main driver of inflam-
mation (36); therefore, its reduction — as observed in Ptpn22–/– mice 
— results in decreased pathology. Since we have shown that the 
presence of the autoimmunity-associated PTPN22 variant results 
in increased expression and secretion of IL-1β in CD patients, our 
data are of relevance for the setting of inflammatory diseases not 
only in mouse models, but also in patients.
Although PTPN22 was able to dephosphorylate NLRP3 directly 
in a cell-free system without assembly of the whole inflammasome 
complex, the interaction of PTPN22 with NLRP3 was dependent 
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ELISA and LDH release assay. Cell culture supernatants and sera 
were collected and stored at –80°C until use. ELISA kits detecting 
human and murine IL-1β were obtained from R&D Systems; anti–
human and anti–mouse IL-18, IL-6, and TNF ELISA kits were obtained 
from PromoKine; and the LDH release assay was from Roche. Assays 
were performed according to the manufacturer’s instructions using 
a sample volume of 100 μl. Absorbance at 450 nm or 490 nm in the 
LDH release assays, with a correction wavelength of 610 nm, was 
detected on a SpectraMax M2 fluorescence microplate reader using 
SoftMax Pro version 5 Software (Molecular Devices). Measurements 
were performed in duplicate.
Test for biological activity of IL-1 in supernatants. IL-1–respon-
sive D10 G4.1 cells (ATCC) were washed 3 times with assay medium 
(RPMI 1640 with 10% FCS and 2.5 μg/ml Concanavalin A; Sigma- 
Aldrich) and incubated for 4 hours at 37°C. Three-fold serial dilutions 
of recombinant IL-1 as standard (500 pg/ml in the first wells) or of cul-
ture supernatants were prepared in duplicate in 96-well plates. D10 
G4.1 cells were then added at 2 × 104 per well to yield a final volume of 
100 μl. After 72 hours of incubation at 37°C in humidified air with 5% 
CO2, 10 μl of a mixture of MTS and PMS was added to the wells accord-
ing to the manufacturer’s instructions (Promega). After 2–4 hours the 
plates were read in an ELISA reader at 490 nm and evaluated using the 
SoftMax software. Each 96-well plate contained an IL-1 standard curve. 
IL-1 specificity of the stimulating activity in the samples was shown by 
adding the IL-1 receptor antagonist (IL-1Ra, 250 ng/ml; Peprotech) to 
some of the assayed supernatants. Inhibition was between 40% and 
80%, depending on the amount of IL-1 in the samples.
Western blotting and immunoprecipitation. Cells or tissue speci-
mens were lysed in M-PER cell lysis buffer (Thermo Fisher Scien-
tific), and immune-reactive proteins were detected using standard 
Western blot methods. Antibodies used were anti–caspase-3 (Cell 
Signaling Technologies [CST]; catalog 9662); anti-NLRP3 (Enzo 
Life Sciences; for mouse: clone Cryo-1, catalog 804-880; for human: 
Nalpy-3a, 804-881); anti-PTPN22 (Santa Cruz Biotechnology Inc.; 
T-16, 48922); anti-ASC (CST; E1E3I, 13833); anti–caspase-1 (CST; 
D7F10, 3866); anti–IL-1β (CST; 3A6, 12242); AIM2 (Santa Cruz 
Biotechnology Inc.; D14; sc-137967); NLRC4 (CST; D5Y8E, 12421); 
PTPN2 (Merck Millipore; CF-41D, PH03L).
For immunoprecipitation, samples were precleared with Sephar-
ose G beads (GE Healthcare) and incubated on a rocker overnight 
at 4°C with 10 μg/ml mouse anti-NLRP3 (Enzo Life Sciences) and 
10 μg/ml goat anti-PTPN22 (Santa Cruz Biotechnology Inc.; T-16, 
48922), prior to precipitation with Sepharose G beads. After washing, 
the pellet was resuspended in 1× loading buffer and boiled for 10 min-
utes at 95°C, and the supernatants were loaded on the gel. For NLRP3 
and pTyr detection in immunoprecipitates, mouse anti-NLRP3 (Enzo 
Life Sciences; Cryo-1, 804-880 or Nalpy-3a, 804-881) and mouse 
anti-pTyr (CST; P-Tyr-100, 9411) antibodies were used. For detection 
of PTPN22, rabbit anti-PTPN22 antibody (Santa Cruz Biotechnology 
Inc.; H-253, sc-134782) was used.
RNA isolation, RT-PCR, and quantitative PCR. Total RNA was iso-
lated using an RNeasy Plus Mini Kit (QIAGEN), and DNA removed 
by a TURBO DNA-free Kit (Ambion) according to the manufacturer’s 
instructions. RNA concentration was assessed by absorbance at 260 
and 280 nm. Complementary DNA (cDNA) synthesis was performed 
using a High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) following the manufacturer’s instructions. Real-time PCR 
number of CD3+ lymphocytes observed in Ptpn22–/– animals. How-
ever, since PTPN22 is involved in T cell biology (39), increased 
numbers of CD3+ cells might well result from a T cell–intrinsic 
effect. Interestingly, the presence of the autoimmunity-associated 
variant also resulted in decreased MPO levels. However, this was 
likely due to overall reduced infiltration and not a defect in granu-
locyte infiltration in response to inflammation.
In summary, we here describe a regulatory mechanism for 
NLRP3, whereby tyrosine phosphorylation counteracts excessive 
NLRP3 activation. It has been described that other inflammasome 
components, such as ASC and NLRC4, are phosphorylated upon 
inflammasome activation (4, 5), suggesting that there are addi-
tional mechanisms involved in enhancing inflammasome activity. 
NLRP3 phosphorylation, in contrast, did not result in activation 
of the inflammasome complex but decreased the activity of the 
receptor. Tyrosine phosphorylation can be activating or inhibi-
tory, depending on the assessed molecule and the context, which 
might explain the opposite effect of tyrosine phosphorylation on 
different inflammasome components. Hence, NLRP3 phosphory-
lation is a regulatory mechanism involved in turning off excessive 
inflammasome activation. As IL-1β is involved in several inflam-
matory disorders, our findings not only describe what we believe 
to be a novel mechanism, but potentially have important implica-
tions for developing new treatment opportunities.
Methods
Cells, vectors, and siRNA treatment. THP-1 and MM6 cells from ATCC were 
maintained in RPMI-1640 medium (Life Technologies) containing 10% 
FCS. To generate BMDCs, bone marrow was flushed from femurs and tib-
iae of mice and plated in RPMI medium supplemented with 10% FCS and 
30% conditioned X63-mGMCSF supernatant (X63-mGMCSF cells were 
generated by our research team). Primary human keratinocytes were iso-
lated, cultured, and activated as described previously (48). PBMCs were 
collected from whole blood using a Ficoll-Paque (GE Healthcare) density 
gradient. Knockdown of PTPN22 was induced in THP-1 and MM6 cells 
using lentiviral particles (Sigma-Aldrich) as described previously (21) or 
in keratinocytes using three different siRNA constructs (Life Technol-
ogies) specifically targeting PTPN22. NLRP3 knockdown was induced 
using siRNA constructs obtained from Life Technologies as described 
previously (21). NLRP3 overexpression vectors were constructed by 
cloning full-length NLRP3 mRNA into a pcDNA3.1-FLAG vector (49). 
pcDNA3.1 vectors expressing a FLAG-tagged WT human/mouse NLRP3 
(NLRP3 WT) or human/mouse NLRP3 with Tyr861>Phe (human) or 
Tyr859>Phe (mouse) (NLRP3 Y>F), Tyr861/859>Glu (NLRP3 Y>E), 
and Tyr861/859>Ala (NLRP3 Y>A) mutations, as well as vectors express-
ing WT, 620/619W, or 263Q PTPN22, were obtained from Geneart. To 
overexpress WT and mutated NLRP3 vectors in BMDCs, the constructs 
were subcloned into a pLKO.1 vector (Sigma-Aldrich), and together with 
pMD2.G and pMCV plasmids (Sigma-Aldrich) used to produce lentiviral 
particles in HEK293T cells as described previously (21).
Inflammasome activation. THP-1 and MM6 cells were differen-
tiated into macrophages by treatment for 3 hours with 50 nM PMA 
(Sigma-Aldrich), and all cells were primed for 12 hours with upLPS 
(Invivogen) prior to inflammasome activation. MSU, ATP, flagellin, 
and MDP were obtained from Invivogen. MDP was transfected into 
the cells using FuGENE transfection reagent (Promega). Flagellin and 
dsDNA were transfected using DOTAP transfection reagent (Roche).
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antibody (Santa Cruz Biotechnology Inc.) was then applied for 1 hour 
at RT and antibody binding visualized by a Liquid DAB+ Substrate 
Chromogen System (Dako). Samples were counterstained with hema-
toxylin, incubated in ethanol and xylol solutions of ascending concen-
trations, and finally mounted. Microscopic assessment was performed 
using an AxioCam HRc (Zeiss) on a Zeiss Axio Imager.Z2 microscope 
with AxioVision release 4.8.2 software.
Patient samples. Intestinal tissue specimens were taken by endoscopy 
from the terminal ileum, colon, or rectum of CD patients with active or 
inactive disease. Biopsy samples were taken from regions appearing 
macroscopically inflamed in patients with active disease and from nor-
mal-appearing regions in patients with quiescent disease. Serum samples 
were collected from a partially overlapping patient group. Patients were 
genotyped for the presence of the PTPN22 rs2476601 and grouped into 
homozygous, heterozygous, and non-carriers for the minor (A) allele. 
The heterozygous and non-carrier groups were matched for age, sex, 
and disease activity. PBMCs were isolated from fresh blood samples 
as described previously (21), CD14+ cells sorted using magnetic beads 
(Miltenyi Biotec), and monocyte-derived dendritic cells differentiated 
for 5 days in RPMI 1640 supplemented with 10% FCS, 500 U hIL-4, and 
1000 U hGM-CSF.
Statistics. Data are presented as mean ± SEM for a series of n exper-
iments. Data are expressed as relative values of the respective control 
groups. Statistical analysis was performed using ANOVA followed by 
Student-Newman-Keuls post hoc test, 2-tailed Student’s t test (cell 
culture experiments), or Mann-Whitney U test (animal experiments 
and patient samples) where appropriate. P values less than 0.05 were 
considered significant.
Study approval. For patient data, written informed consent was 
obtained before specimen collection, and studies were approved by 
the local Ethics Committee (Ethikkommission des Kantons Zürich, 
Zurich, Switzerland). Mouse experiments were performed with the 
approval of the local animal welfare authority (Tierschutzkommision 
Zürich, Zurich, Switzerland).
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